APO Research
Talk to an analyst

APO RESEARCH · REPORT

KRAS G12C Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global KRAS G12C Inhibitors Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchKRAS G12C Inhibitors Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal KRAS G12C Inhibitors Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal KRAS G12C Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal KRAS G12C Inhibitors Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal KRAS G12C Inhibitors Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global KRAS G12C Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for KRAS G12C Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for KRAS G12C Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for KRAS G12C Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the KRAS G12C Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the KRAS G12C Inhibitors market include Innovent Biologics, Inc., Genfleet Therapeutics (Shanghai), Inc., Amgen and Mirati Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global KRAS G12C Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of KRAS G12C Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents KRAS G12C Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the KRAS G12C Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

KRAS G12C Inhibitors Segment by Company

Innovent Biologics, Inc.

Genfleet Therapeutics (Shanghai), Inc.

Amgen

Mirati Therapeutics

KRAS G12C Inhibitors Segment by Type

Adagrasib

Fulzerasib

Garsorasib

Sotorasib

KRAS G12C Inhibitors Segment by Application

Hospital

Clinic

Others

KRAS G12C Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global KRAS G12C Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions KRAS G12C Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify KRAS G12C Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze KRAS G12C Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS G12C Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KRAS G12C Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS G12C Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the KRAS G12C Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global KRAS G12C Inhibitors industry.

Chapter 3: Detailed analysis of KRAS G12C Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of KRAS G12C Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of KRAS G12C Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. KRAS G12C Inhibitors Industry Trends Table 2. KRAS G12C Inhibitors Industry Drivers Table 3. KRAS G12C Inhibitors Industry Opportunities and Challenges Table 4. KRAS G12C Inhibitors Industry Restraints Table 5. Global KRAS G12C Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global KRAS G12C Inhibitors Revenue Share by Company (2021-2026) Table 7. Global KRAS G12C Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global KRAS G12C Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global KRAS G12C Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global KRAS G12C Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global KRAS G12C Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global KRAS G12C Inhibitors Company, Product Type & Application Table 13. Global KRAS G12C Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global KRAS G12C Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Adagrasib Table 18. Significant Companies of Fulzerasib Table 19. Significant Companies of Garsorasib Table 20. Significant Companies of Sotorasib Table 21. Global KRAS G12C Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global KRAS G12C Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 23. Global KRAS G12C Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 24. Global KRAS G12C Inhibitors Sales Volume Share by Type (2021-2026) Table 25. Global KRAS G12C Inhibitors Sales Volume Share by Type (2027-2032) Table 26. Global KRAS G12C Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global KRAS G12C Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global KRAS G12C Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global KRAS G12C Inhibitors Sales Value Share by Type (2021-2026) Table 30. Global KRAS G12C Inhibitors Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global KRAS G12C Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global KRAS G12C Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 36. Global KRAS G12C Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 37. Global KRAS G12C Inhibitors Sales Volume Share by Application (2021-2026) Table 38. Global KRAS G12C Inhibitors Sales Volume Share by Application (2027-2032) Table 39. Global KRAS G12C Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global KRAS G12C Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global KRAS G12C Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global KRAS G12C Inhibitors Sales Value Share by Application (2021-2026) Table 43. Global KRAS G12C Inhibitors Sales Value Share by Application (2027-2032) Table 44. Global KRAS G12C Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global KRAS G12C Inhibitors Sales by Region (2021-2026) & (K Units) Table 46. Global KRAS G12C Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global KRAS G12C Inhibitors Sales by Region (2027-2032) & (K Units) Table 48. Global KRAS G12C Inhibitors Sales Market Share by Region (2027-2032) Table 49. Global KRAS G12C Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global KRAS G12C Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global KRAS G12C Inhibitors Sales Value Share by Region (2021-2026) Table 52. Global KRAS G12C Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global KRAS G12C Inhibitors Sales Value Share by Region (2027-2032) Table 54. Global KRAS G12C Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global KRAS G12C Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global KRAS G12C Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global KRAS G12C Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global KRAS G12C Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. Global KRAS G12C Inhibitors Sales Market Share by Country (2021-2026) Table 60. Global KRAS G12C Inhibitors Sales by Country (2027-2032) & (K Units) Table 61. Global KRAS G12C Inhibitors Sales Market Share by Country (2027-2032) Table 62. Global KRAS G12C Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global KRAS G12C Inhibitors Sales Value Market Share by Country (2021-2026) Table 64. Global KRAS G12C Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global KRAS G12C Inhibitors Sales Value Market Share by Country (2027-2032) Table 66. Innovent Biologics, Inc. Company Information Table 67. Innovent Biologics, Inc. Business Overview Table 68. Innovent Biologics, Inc. KRAS G12C Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Innovent Biologics, Inc. KRAS G12C Inhibitors Product Portfolio Table 70. Innovent Biologics, Inc. Recent Development Table 71. Genfleet Therapeutics (Shanghai), Inc. Company Information Table 72. Genfleet Therapeutics (Shanghai), Inc. Business Overview Table 73. Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Product Portfolio Table 75. Genfleet Therapeutics (Shanghai), Inc. Recent Development Table 76. Amgen Company Information Table 77. Amgen Business Overview Table 78. Amgen KRAS G12C Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Amgen KRAS G12C Inhibitors Product Portfolio Table 80. Amgen Recent Development Table 81. Mirati Therapeutics Company Information Table 82. Mirati Therapeutics Business Overview Table 83. Mirati Therapeutics KRAS G12C Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Mirati Therapeutics KRAS G12C Inhibitors Product Portfolio Table 85. Mirati Therapeutics Recent Development Table 86. Key Raw Materials Table 87. Raw Materials Key Suppliers Table 88. KRAS G12C Inhibitors Distributors List Table 89. KRAS G12C Inhibitors Customers List Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. KRAS G12C Inhibitors Product Image Figure 2. Global KRAS G12C Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global KRAS G12C Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global KRAS G12C Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global KRAS G12C Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global KRAS G12C Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Adagrasib Image Figure 10. Fulzerasib Image Figure 11. Garsorasib Image Figure 12. Sotorasib Image Figure 13. Global KRAS G12C Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global KRAS G12C Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global KRAS G12C Inhibitors Sales Volume Share by Type (2021-2032) Figure 16. Global KRAS G12C Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global KRAS G12C Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global KRAS G12C Inhibitors Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global KRAS G12C Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global KRAS G12C Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global KRAS G12C Inhibitors Sales Volume Share by Application (2021-2032) Figure 25. Global KRAS G12C Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global KRAS G12C Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global KRAS G12C Inhibitors Sales Value Share by Application (2021-2032) Figure 28. Global KRAS G12C Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global KRAS G12C Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global KRAS G12C Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global KRAS G12C Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America KRAS G12C Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 33. North America KRAS G12C Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe KRAS G12C Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. Europe KRAS G12C Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific KRAS G12C Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific KRAS G12C Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America KRAS G12C Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. South America KRAS G12C Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa KRAS G12C Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa KRAS G12C Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. KRAS G12C Inhibitors Value Chain Figure 127. Manufacturing Cost Structure Figure 128. KRAS G12C Inhibitors Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Adagrasib
  • Fulzerasib
  • Garsorasib
  • Sotorasib
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Innovent Biologics, Inc.
  • Genfleet Therapeutics (Shanghai), Inc.
  • Amgen
  • Mirati Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global KRAS G12C Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global KRAS G12C Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global KRAS G12C Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 KRAS G12C Inhibitors Market Dynamics
  1. 2.1 KRAS G12C Inhibitors Industry Trends
  2. 2.2 KRAS G12C Inhibitors Industry Drivers
  3. 2.3 KRAS G12C Inhibitors Industry Opportunities and Challenges
  4. 2.4 KRAS G12C Inhibitors Industry Restraints
3 KRAS G12C Inhibitors Market by Company
  1. 3.1 Global KRAS G12C Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global KRAS G12C Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global KRAS G12C Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global KRAS G12C Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global KRAS G12C Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global KRAS G12C Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global KRAS G12C Inhibitors Company Product Type and Application
  8. 3.8 Global KRAS G12C Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global KRAS G12C Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 KRAS G12C Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 KRAS G12C Inhibitors Market by Type
  1. 4.1 KRAS G12C Inhibitors Type Introduction
  2. 4.1.1 Adagrasib
  3. 4.1.2 Fulzerasib
  4. 4.1.3 Garsorasib
  5. 4.1.4 Sotorasib
  6. 4.2 Global KRAS G12C Inhibitors Sales Volume by Type
  7. 4.2.1 Global KRAS G12C Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global KRAS G12C Inhibitors Sales Volume by Type (2021-2032)
  9. 4.2.3 Global KRAS G12C Inhibitors Sales Volume Share by Type (2021-2032)
  10. 4.3 Global KRAS G12C Inhibitors Sales Value by Type
  11. 4.3.1 Global KRAS G12C Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global KRAS G12C Inhibitors Sales Value by Type (2021-2032)
  13. 4.3.3 Global KRAS G12C Inhibitors Sales Value Share by Type (2021-2032)
5 KRAS G12C Inhibitors Market by Application
  1. 5.1 KRAS G12C Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global KRAS G12C Inhibitors Sales Volume by Application
  6. 5.2.1 Global KRAS G12C Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global KRAS G12C Inhibitors Sales Volume by Application (2021-2032)
  8. 5.2.3 Global KRAS G12C Inhibitors Sales Volume Share by Application (2021-2032)
  9. 5.3 Global KRAS G12C Inhibitors Sales Value by Application
  10. 5.3.1 Global KRAS G12C Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global KRAS G12C Inhibitors Sales Value by Application (2021-2032)
  12. 5.3.3 Global KRAS G12C Inhibitors Sales Value Share by Application (2021-2032)
6 KRAS G12C Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global KRAS G12C Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global KRAS G12C Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global KRAS G12C Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global KRAS G12C Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global KRAS G12C Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global KRAS G12C Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global KRAS G12C Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global KRAS G12C Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global KRAS G12C Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America KRAS G12C Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America KRAS G12C Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe KRAS G12C Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe KRAS G12C Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific KRAS G12C Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific KRAS G12C Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America KRAS G12C Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America KRAS G12C Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa KRAS G12C Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa KRAS G12C Inhibitors Sales Value Share by Country, 2025 VS 2032
7 KRAS G12C Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global KRAS G12C Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global KRAS G12C Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global KRAS G12C Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global KRAS G12C Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global KRAS G12C Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global KRAS G12C Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global KRAS G12C Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global KRAS G12C Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt KRAS G12C Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt KRAS G12C Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt KRAS G12C Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Innovent Biologics, Inc.
  2. 8.1.1 Innovent Biologics, Inc. Company Information
  3. 8.1.2 Innovent Biologics, Inc. Business Overview
  4. 8.1.3 Innovent Biologics, Inc. KRAS G12C Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Innovent Biologics, Inc. KRAS G12C Inhibitors Product Portfolio
  6. 8.1.5 Innovent Biologics, Inc. Recent Developments
  7. 8.2 Genfleet Therapeutics (Shanghai), Inc.
  8. 8.2.1 Genfleet Therapeutics (Shanghai), Inc. Company Information
  9. 8.2.2 Genfleet Therapeutics (Shanghai), Inc. Business Overview
  10. 8.2.3 Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Product Portfolio
  12. 8.2.5 Genfleet Therapeutics (Shanghai), Inc. Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen KRAS G12C Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amgen KRAS G12C Inhibitors Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Mirati Therapeutics
  20. 8.4.1 Mirati Therapeutics Company Information
  21. 8.4.2 Mirati Therapeutics Business Overview
  22. 8.4.3 Mirati Therapeutics KRAS G12C Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mirati Therapeutics KRAS G12C Inhibitors Product Portfolio
  24. 8.4.5 Mirati Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 KRAS G12C Inhibitors Value Chain Analysis
  2. 9.1.1 KRAS G12C Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 KRAS G12C Inhibitors Sales Mode & Process
  6. 9.2 KRAS G12C Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 KRAS G12C Inhibitors Distributors
  9. 9.2.3 KRAS G12C Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst